Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Niacin-ER Clear all
Completed Phase 2 Interventional Results available

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

NCT01426438
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Niacin, Aspirin, Fenofibrate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 4, 2026, 1:43 PM EDT
Completed Phase 3 Interventional

The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC

NCT00071266
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Disease
Interventions
Niacin Extended Release and Lovastatin Tablets
Drug
Lead sponsor
Kos Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2006 · Synced Sep 4, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

NCT01194869
View directory record Official record
Conditions
Breast Cancer
Interventions
Sorafenib, Cisplatin, Paclitaxel
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 4, 2026, 1:43 PM EDT
Terminated Phase 1 Interventional Results available

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

NCT02702492
View directory record Official record
Conditions
Solid Tumors, NHL
Interventions
KPT-9274, Niacin ER, Nivolumab
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 4, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

NCT02624700
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions
Experimental Arm A: Pemetrexed, Experimental Arm A: Sorafenib, Experimental Arm B: Pemetrexed, Experimental Arm B: Sorafenib
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 4, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
View directory record Official record
Conditions
Healthy
Interventions
atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 4, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

NCT00465088
View directory record Official record
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Niacin ER/Simvastatin Tablets, atorvastatin
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
46
States / cities
Anaheim, California • Huntington Park, California • Long Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2011 · Synced Sep 4, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

NCT00728910
View directory record Official record
Conditions
Dyslipidemia
Interventions
Atorvastatin, ABT335, ER Niacin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 4, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Effects of Niacin Therapy on Lipoprotein Composition and Function

NCT02322203
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Niacin Extended Release
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 4, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

NCT00573755
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, exemestane, letrozole, sorafenib tosylate, placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 4, 2026, 1:43 PM EDT
Withdrawn Phase 1Phase 2 Interventional

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

NCT03563170
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Interventions
ETBX-011, GI-4000, haNK for infusion, avelumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, SBRT, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, Cetuximab, N-803
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 4, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Psyllium on Niacin Tolerability

NCT03370848
View directory record Official record
Conditions
Flushing, Hyperlipidemias, Dyslipidemias
Interventions
Psyllium, Aspirin
Dietary Supplement · Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 4, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Niacin to Improve Blood Flow in People With Sickle Cell Disease

NCT00508989
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Niacin-ER, Placebo, L-NMMA, Acetylcholine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 4, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

Effects of Niacin On Fatty Acid Trapping

NCT01984073
View directory record Official record
Conditions
Dyslipidemia
Interventions
ER Niacin Oral Fat Challenge, IR Niacin Oral Fat Challenge, Placebo Oral Fat Challenge
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 4, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

NCT00300365
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pioglitazone, Placebo, Niacin ER, Aspirin
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Sep 4, 2026, 1:43 PM EDT